Study analysis · Proceedings of the National Academy of Sciences · 2016
This one shot made old mice 20% stronger—could it work for humans?
A special shot blocked a muscle-limiting protein and made old mice stronger and better at using sugar, but only in old mice, not young ones.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tested a special medicine on old mice and found that their muscles got bigger and stronger, and their bodies handled sugar a little better. But it didn't prove the medicine caused these changes for sure — it just showed they happened together.
What’s the bottom line?
Scientists gave old mice a special shot that blocks a protein that stops muscles from growing. After 4 weeks, the mice got stronger and their muscles used sugar better.
How strong is this study?
The scientists did a good job giving some mice the medicine and others nothing, and they measured things carefully. But they only used 10 mice per group, didn't hide which mice got the medicine, and only used male mice — so we can't be super sure the results are reliable or will work in people.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Although randomization was used, this is an animal study with a very small sample size (n=10 per group), no blinding reported, and findings cannot be directly generalized to humans. Randomization alone does not override the limitations of animal models and small samples for establishing human causation.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Atara Biotherapeutics, a company developing anti-myostatin therapies, and two authors are employees of the company, raising concerns about potential influence on study design and interpretation.
Funders
Conflict Details
Atara Biotherapeutics: Employee of Atara Biotherapeutics
Atara Biotherapeutics: Employee of Atara Biotherapeutics
While academic institutions (Yale, Pittsburgh) are primary contributors, the involvement of industry employees in study design and provision of reagents creates a significant conflict. No statement was found regarding independent data analysis or publication oversight.
Key takeaways
- 01
Muscle mass went up by 7%, grip strength by 20%, and muscle sugar use improved by 16%.
- 02
Fat in muscles dropped by 30%.
- 03
But energy use didn't go up.
- 04
For an older person, this could mean less frailty and better blood sugar control — but it's not clear if the same effect happens in humans.
Surprising findings
- Increasing muscle mass didn't increase energy expenditure in old mice.Everyone assumes bigger muscles burn more calories, but this study found no change in metabolism—even with 7% more muscle.
- Myostatin inhibition improved insulin sensitivity only in old mice, not young ones—even when young mice gained similar muscle mass.It suggests aging changes how muscle responds to growth signals—muscle isn't just muscle; its function depends on age.
Practical takeaways
If you're over 60 and losing strength, prioritize resistance training—it may mimic the muscle-building effects of this antibody.
This antibody hasn't been proven safe or effective in humans, and the study was only 4 weeks long in mice.
medium confidenceDon't assume building muscle will automatically improve your blood sugar—focus on diet quality and sleep too.
The study showed muscle growth without metabolic benefit in young mice on a high-fat diet.
high confidenceWhy this study matters
Muscle Boost in Old Mice
In old male mice, a 4-week treatment with an anti-myostatin antibody (ATA 842) increased lean body mass by 7% and grip strength by 20%, directly reversing age-related muscle loss.
This could mean a future therapy for elderly humans to fight frailty, falls, and loss of independence—without needing intense exercise.
Sugar Use Improved, But Not Energy Burn
Despite gaining 7% more muscle, old mice didn't burn more calories—energy expenditure stayed the same, contradicting the assumption that more muscle = more metabolism.
It challenges the common belief that building muscle automatically boosts your metabolism—this study says it might not, at least not with small gains.
It Worked in Old Mice, Not Young Ones
While young mice gained muscle and lost fat on a high-fat diet, their insulin sensitivity didn't improve—showing muscle growth alone can't fix diet-induced metabolic disease.
This flips the script: Even if you build muscle, junk food can still wreck your blood sugar. Diet matters more than you think.
Fat Inside Muscles Dropped by 30%
Intramuscular triglycerides—fat stored inside muscle cells—fell by 30% in old mice, which is linked to better insulin sensitivity and reduced diabetes risk.
This fat isn't visible—it's hidden inside your muscles and is a silent driver of type 2 diabetes. This treatment cleared it out.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave old mice a special shot that blocks a protein that stops muscles from growing. After 4 weeks, the mice got stronger and their muscles used sugar better.
Research results
Muscle mass went up by 7%, grip strength by 20%, and muscle sugar use improved by 16%. Fat in muscles dropped by 30%. But energy use didn't go up.
What this means - more context
For an older person, this could mean less frailty and better blood sugar control — but it's not clear if the same effect happens in humans.
This study investigates whether inhibiting myostatin with an antibody (ATA 842) can reverse age-related muscle loss (sarcopenia) and improve metabolic function in mice.
In old male mice, a 4-week anti-myostatin antibody treatment increased lean body mass by ~7% and grip strength by ~20%, improved insulin-stimulated muscle glucose uptake by 16%, and reduced intramuscular triglycerides by ~30%. In young mice, it increased muscle mass and reduced fat on a high-fat diet but did not improve insulin sensitivity. Energy expenditure did not increase in old mice despite muscle gain.
Methods Used
Experimental study in male mice (young: 10 weeks; old: 22 months) treated with ATA 842 antibody (20 mg/kg/week) or vehicle for 4 weeks. Outcomes measured via 1H-NMR for body composition, grip strength test, hyperinsulinemic-euglycemic clamp for insulin sensitivity, and tissue triglyceride assays.
Main Finding
In old male mice, 4 weeks of anti-myostatin antibody treatment increased lean mass by ~7%, grip strength by ~20%, and insulin-stimulated muscle glucose uptake by 16%, without increasing whole-body energy expenditure.
Confidence Level
High — controlled experimental design with direct physiological measurements (e.g., hyperinsulinemic-euglycemic clamp), clear effect sizes, and replication across multiple endpoints.
Study Flags
Red Flags
- •Animal study (mice only), human relevance unknown
- •Funding from company that manufactures the antibody (Atara Biotherapeutics)
- •Small sample size (n=10 per group) and short duration (4 weeks)
Surprising Findings
Increasing muscle mass didn't increase energy expenditure in old mice.
Everyone assumes bigger muscles burn more calories, but this study found no change in metabolism—even with 7% more muscle.
Practical Takeaways
If you're over 60 and losing strength, prioritize resistance training—it may mimic the muscle-building effects of this antibody.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study tested a special medicine on old mice and found that their muscles got bigger and stronger, and their bodies handled sugar a little better. But it didn't prove the medicine caused these changes for sure — it just showed they happened together.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Used randomized assignment to treatment groups
- Included appropriate control groups
- Used gold-standard metabolic measurements (hyperinsulinemic-euglycemic clamp)
Weaknesses
- No blinding reported — risk of measurement bias
- Very small sample size (n=10 per group)
- Only male mice studied — limits generalizability to females
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave old mice a special shot that blocks a protein that stops muscles from growing. After 4 weeks, the mice got stronger and their muscles used sugar better.
Research results
Muscle mass went up by 7%, grip strength by 20%, and muscle sugar use improved by 16%. Fat in muscles dropped by 30%. But energy use didn't go up.
What this means - more context
For an older person, this could mean less frailty and better blood sugar control — but it's not clear if the same effect happens in humans.
This study investigates whether inhibiting myostatin with an antibody (ATA 842) can reverse age-related muscle loss (sarcopenia) and improve metabolic function in mice.
In old male mice, a 4-week anti-myostatin antibody treatment increased lean body mass by ~7% and grip strength by ~20%, improved insulin-stimulated muscle glucose uptake by 16%, and reduced intramuscular triglycerides by ~30%. In young mice, it increased muscle mass and reduced fat on a high-fat diet but did not improve insulin sensitivity. Energy expenditure did not increase in old mice despite muscle gain.
Methods Used
Experimental study in male mice (young: 10 weeks; old: 22 months) treated with ATA 842 antibody (20 mg/kg/week) or vehicle for 4 weeks. Outcomes measured via 1H-NMR for body composition, grip strength test, hyperinsulinemic-euglycemic clamp for insulin sensitivity, and tissue triglyceride assays.
Main Finding
In old male mice, 4 weeks of anti-myostatin antibody treatment increased lean mass by ~7%, grip strength by ~20%, and insulin-stimulated muscle glucose uptake by 16%, without increasing whole-body energy expenditure.
Confidence Level
High — controlled experimental design with direct physiological measurements (e.g., hyperinsulinemic-euglycemic clamp), clear effect sizes, and replication across multiple endpoints.
Study Flags
Red Flags
- •Animal study (mice only), human relevance unknown
- •Funding from company that manufactures the antibody (Atara Biotherapeutics)
- •Small sample size (n=10 per group) and short duration (4 weeks)
Surprising Findings
Increasing muscle mass didn't increase energy expenditure in old mice.
Everyone assumes bigger muscles burn more calories, but this study found no change in metabolism—even with 7% more muscle.
Practical Takeaways
If you're over 60 and losing strength, prioritize resistance training—it may mimic the muscle-building effects of this antibody.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study tested a special medicine on old mice and found that their muscles got bigger and stronger, and their bodies handled sugar a little better. But it didn't prove the medicine caused these changes for sure — it just showed they happened together.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Used randomized assignment to treatment groups
- Included appropriate control groups
- Used gold-standard metabolic measurements (hyperinsulinemic-euglycemic clamp)
Weaknesses
- No blinding reported — risk of measurement bias
- Very small sample size (n=10 per group)
- Only male mice studied — limits generalizability to females
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a good job giving some mice the medicine and others nothing, and they measured things carefully. But they only used 10 mice per group, didn't hide which mice got the medicine, and only used male mice — so we can't be super sure the results are reliable or will work in people.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
57 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Although randomization was used, this is an animal study with a very small sample size (n=10 per group), no blinding reported, and findings cannot be directly generalized to humans. Randomization alone does not override the limitations of animal models and small samples for establishing human causation.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Atara Biotherapeutics, a company developing anti-myostatin therapies, and two authors are employees of the company, raising concerns about potential influence on study design and interpretation.
Funders
Conflict Details
Atara Biotherapeutics: Employee of Atara Biotherapeutics
Atara Biotherapeutics: Employee of Atara Biotherapeutics
While academic institutions (Yale, Pittsburgh) are primary contributors, the involvement of industry employees in study design and provision of reagents creates a significant conflict. No statement was found regarding independent data analysis or publication oversight.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence